Abstract:
The world health organization recommends the use of Pyrazinamide for first line antituberculosis drug for the treatment of TB. Developing age-appropriate dosage forms is critical for effective pharmaceutical therapy, particularly chronic conditions like paediatric Tuberculosis (TB) requiring prolonged treatment. This study aimed to develop 3D printing tablets using Hot Melt Extrusion (HME) to produce drug loaded filaments for subsequent 3D printing via Fused Deposition Modeling (FDM). Pyrazinamide and Polyvinyl Alcohol (PVA) were used to fabricate PZA-loaded PVA 3D printed tablets. The printed tablets were evaluated for key pharmaceutical parameters including in vitro dissolution, friability, hardness, disintegration and weight variation within <±5%. The fabricated pyrazinamide 3D printed tablet showed cumulative drug release of 92.67% within 0-150 minute. This work highlights a novel approach for producing paediatric TB formulations through 3D printing, offering potential for personalized dosing and improved treatment compliance in paediatric patients.
